作者:Masayuki Matsushita、Timothy Z Hoffman、Jon A Ashley、Bin Zhou、Peter Wirsching、Kim D Janda
DOI:10.1016/s0960-894x(00)00659-4
日期:2001.1
Current treatments for cocaine addiction are not effective. The development of a catalytic monoclonal antibody (mAb) provides a strategy for not only binding, but also degrading cocaine, which offers a broad-based therapy. Hapten design is the central element for programming antibody catalysis. The characteristics of the linker used in classic transition-state analogue phosphonate haptens were shown to be important for obtaining mAbs that hydrolyze the benzoate ester of cocaine. (C) 2001 Elsevier Science Ltd. All rights reserved.